|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2662-2668.
Prepublished online as a Blood First Edition Paper on June 15, 2006; DOI 10.1182/blood-2006-04-017566.
 Previous Article | Next Article 
Submitted April 17, 2006
Accepted June 3, 2006
Identification of an immunogenic CD8+ T cell epitope derived from  -globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia
Naoto Hirano*, Marcus Butler, Zhinan Xia, Alla Berezovskaya, Andrew P Murray, Sascha Ansen, Seiji Kojima, and Lee M Nadler
Department of Medical Oncology, Dana-Farber Cancer Institute; Brigham and Women's Hospital, Boston
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA,USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Department of Pediatrics, Nagoya University, Nagoya, Japan
* Corresponding author; email: naoto_hirano{at}dfci.harvard.edu.
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder. Although allogeneic stem cell transplantation can induce long-term remissions, relapse rates remain high and innovative approaches are needed. Since donor lymphocyte infusions have clinical activity in JMML, T cell mediated immunotherapy could provide a nonredundant treatment approach to compliment current therapies.  -Globin, an oncofetal protein overexpressed by clonogenic JMML cells, may serve as a target of an anti-tumor immune response. We predicted 5 -globin derived peptides as potential HLA-A2 restricted CTL epitopes and showed that 4 (g031, g071, g105, and g106) bind A2 molecules in vitro. Using an artificial antigen presenting cell (aAPC) that can process both the N- and C-termini of endogenously expressed proteins, we biochemically confirmed that g105 is naturally processed and presented by cell surface A2. Furthermore, g105 specific CD8+ CTL generated from A2 positive healthy donors were able to specifically cytolyze -globin+, but not -globin-, JMML cells in an A2 restricted manner. These results suggest that this aAPC-based approach enables the biochemical identification of CD8+ T cell epitopes that are processed and presented by intact cells and that CTL immunotherapy of JMML could be directed against the -globin derived epitope g105.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Komita, X. Zhao, J. L. Taylor, L. J. Sparvero, A. A. Amoscato, S. Alber, S. C. Watkins, A. D. Pardee, A. K. Wesa, and W. J. Storkus
CD8+ T-Cell Responses against Hemoglobin-{beta} Prevent Solid Tumor Growth
Cancer Res.,
October 1, 2008;
68(19):
8076 - 8084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ansen, M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano
Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21
Clin. Cancer Res.,
October 1, 2008;
14(19):
6125 - 6136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Domchek, A. Recio, R. Mick, C. E. Clark, E. L. Carpenter, K. R. Fox, A. DeMichele, L. M. Schuchter, M. S. Leibowitz, M. H. Wexler, et al.
Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance
Cancer Res.,
November 1, 2007;
67(21):
10546 - 10555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
